3/19
11:47 am
arvn
Arvinas (ARVN) had its price target raised by Citigroup Inc. from $18.00 to $21.00. They now have a "buy" rating on the stock.
Medium
Report
Arvinas (ARVN) had its price target raised by Citigroup Inc. from $18.00 to $21.00. They now have a "buy" rating on the stock.
3/19
08:52 am
arvn
Arvinas (ARVN) had its price target raised by BTIG Research from $14.00 to $16.00. They now have a "buy" rating on the stock.
Medium
Report
Arvinas (ARVN) had its price target raised by BTIG Research from $14.00 to $16.00. They now have a "buy" rating on the stock.
3/18
03:01 pm
arvn
Arvinas (ARVN) was given a new $10.00 price target by Truist Financial Corporation.
Low
Report
Arvinas (ARVN) was given a new $10.00 price target by Truist Financial Corporation.
3/18
07:40 am
arvn
Arvinas Announces Positive Phase 1 Data for ARV-102 Showing Greater Than 50% LRRK2 Degradation in the CSF of Patients with Parkinson's Disease Treated for 28 Days [Yahoo! Finance]
Medium
Report
Arvinas Announces Positive Phase 1 Data for ARV-102 Showing Greater Than 50% LRRK2 Degradation in the CSF of Patients with Parkinson's Disease Treated for 28 Days [Yahoo! Finance]
3/18
07:00 am
arvn
Arvinas Announces Positive Phase 1 Data for ARV-102 Showing Greater Than 50% LRRK2 Degradation in the CSF of Patients with Parkinson’s Disease Treated for 28 Days
High
Report
Arvinas Announces Positive Phase 1 Data for ARV-102 Showing Greater Than 50% LRRK2 Degradation in the CSF of Patients with Parkinson’s Disease Treated for 28 Days
3/11
08:04 pm
arvn
Arvinas Highlights Phase 1 Shift, 2026 Data Catalysts, and Vepdegestrant NDA at Barclays Conference [Yahoo! Finance]
Medium
Report
Arvinas Highlights Phase 1 Shift, 2026 Data Catalysts, and Vepdegestrant NDA at Barclays Conference [Yahoo! Finance]
3/11
07:37 am
arvn
Arvinas to Present Phase 1 Data for ARV-102, a PROTAC LRRK2 Degrader, in Oral Session at the 2026 International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders [Yahoo! Finance]
Low
Report
Arvinas to Present Phase 1 Data for ARV-102, a PROTAC LRRK2 Degrader, in Oral Session at the 2026 International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders [Yahoo! Finance]
3/11
07:00 am
arvn
Arvinas to Present Phase 1 Data for ARV-102, a PROTAC LRRK2 Degrader, in Oral Session at the 2026 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders
Low
Report
Arvinas to Present Phase 1 Data for ARV-102, a PROTAC LRRK2 Degrader, in Oral Session at the 2026 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders
3/10
05:38 pm
arvn
Arvinas, Inc. (ARVN) Presents at Barclays 28th Annual Global Healthcare Conference Transcript [Seeking Alpha]
Low
Report
Arvinas, Inc. (ARVN) Presents at Barclays 28th Annual Global Healthcare Conference Transcript [Seeking Alpha]
3/10
03:13 am
arvn
Arvinas Teases Near-Term Phase 1 Data, Eyes New Vepdegestrant Partner at Leerink Conference [Yahoo! Finance]
Low
Report
Arvinas Teases Near-Term Phase 1 Data, Eyes New Vepdegestrant Partner at Leerink Conference [Yahoo! Finance]
3/6
07:03 pm
arvn
How The Arvinas (ARVN) Narrative Is Evolving With New Leadership And Key 2026 Pipeline Catalysts [Yahoo! Finance]
Medium
Report
How The Arvinas (ARVN) Narrative Is Evolving With New Leadership And Key 2026 Pipeline Catalysts [Yahoo! Finance]
3/5
02:22 pm
arvn
Arvinas (ARVN) had its price target raised by Citigroup Inc. from $15.00 to $18.00. They now have a "buy" rating on the stock.
Low
Report
Arvinas (ARVN) had its price target raised by Citigroup Inc. from $15.00 to $18.00. They now have a "buy" rating on the stock.
3/4
10:57 am
arvn
Arvinas Highlights Growing Phase 1 Pipeline, Near-Term Catalysts at TD Cowen Healthcare Conference [Yahoo! Finance]
Low
Report
Arvinas Highlights Growing Phase 1 Pipeline, Near-Term Catalysts at TD Cowen Healthcare Conference [Yahoo! Finance]
3/3
10:05 am
arvn
Prostate Cancer Market Competitive Landscape Report 2026: Comprehensive Insights About 230+ Companies and 265+ Drugs by Product Type, Stage, and Route of Administration [Yahoo! Finance]
Low
Report
Prostate Cancer Market Competitive Landscape Report 2026: Comprehensive Insights About 230+ Companies and 265+ Drugs by Product Type, Stage, and Route of Administration [Yahoo! Finance]
3/2
04:10 am
arvn
Arvinas, Inc. (ARVN) Makes Significant Progress on Oncology and Neurology Trials [Yahoo! Finance]
Low
Report
Arvinas, Inc. (ARVN) Makes Significant Progress on Oncology and Neurology Trials [Yahoo! Finance]
3/2
01:00 am
arvn
Low
Report
2/25
09:39 am
arvn
Arvinas (ARVN) had its "overweight" rating reaffirmed by Piper Sandler. They now have a $20.00 price target on the stock, up from $16.00.
Low
Report
Arvinas (ARVN) had its "overweight" rating reaffirmed by Piper Sandler. They now have a $20.00 price target on the stock, up from $16.00.
2/24
07:03 pm
arvn
Arvinas Inc (ARVN) Q4 2025 Earnings Call Highlights: Navigating Revenue Challenges with ... [Yahoo! Finance]
Medium
Report
Arvinas Inc (ARVN) Q4 2025 Earnings Call Highlights: Navigating Revenue Challenges with ... [Yahoo! Finance]
2/24
03:08 pm
arvn
Arvinas (ARVN) had its "neutral" rating reaffirmed by Wedbush.
Low
Report
Arvinas (ARVN) had its "neutral" rating reaffirmed by Wedbush.
2/24
02:11 pm
arvn
Arvinas (ARVN) Q4 2025 Earnings Call Transcript [Yahoo! Finance]
Low
Report
Arvinas (ARVN) Q4 2025 Earnings Call Transcript [Yahoo! Finance]
2/24
12:43 pm
arvn
Arvinas, Inc. Q4 2025 Earnings Call Summary [Yahoo! Finance]
Medium
Report
Arvinas, Inc. Q4 2025 Earnings Call Summary [Yahoo! Finance]
2/24
10:56 am
arvn
Arvinas Q4 Earnings Call Highlights [Yahoo! Finance]
Low
Report
Arvinas Q4 Earnings Call Highlights [Yahoo! Finance]
2/24
07:00 am
arvn
Arvinas Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Medium
Report
Arvinas Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
2/23
10:12 am
arvn
Arvinas Inc (ARVN) Q4 2025: Everything You Need To Know Ahead Of Earnings [Yahoo! Finance]
Low
Report
Arvinas Inc (ARVN) Q4 2025: Everything You Need To Know Ahead Of Earnings [Yahoo! Finance]
2/23
07:18 am
arvn
Arvinas to Participate in Upcoming Investor Conferences [Yahoo! Finance]
Low
Report
Arvinas to Participate in Upcoming Investor Conferences [Yahoo! Finance]